Our results suggested an improved survival benefit at 28-day mortality in septic patients with CHD between the albumin infusion group and the non-albumin infusion group (HR, 0.54; 95% CI: 0.38–0.78; p = 0.0009). Here, ALB is linked to coronary artery disorder.